Introduction
AIDS continues to be a serious health problem in the United States and worldwide. Highly active antiretroviral therapy has greatly reduced viral loads and reduced morbidity and mortality from AIDS, 1 but the side effects can be severe 2 and the emergence of drug resistance is a problem. Despite substantial efforts to develop a vaccine, [3] [4] [5] there is still no cure and alternative therapies need to be explored. One approach to cure AIDS has been by transplantation with genetically modified cells that inhibit human immunodeficiency virus (HIV) replication. Many synthetic genes have been developed that can inhibit replication of HIV-1 with a gene therapy approach using T lymphocytes or hematopoietic stem cells (HSCs) (reviewed in Rossi et al. 6 ). One limitation in targeting mature lymphocytes for gene therapy, the predominant host cell for HIV-1 infection, is the limited number and persistence of engrafted gene-modified T cells observed in AIDS gene therapy studies. 7 The ability of HSCs to reconstitute the entire hematopoietic system, including T lymphocytes, macrophages, dendritic cells and microglial cells, suggests that they are ideal targets for AIDS gene therapy. However, the inability to efficiently deliver anti-HIV transgenes to HSCs has been a major roadblock in clinical trials. In a phase I clinical trial using bone marrow-derived CD34 + cells transduced with a Moloney leukemia virus (MLV) vector containing a Rev response element decoy, short-term marking rates of 0.003-0.01% and long-term marking rates o0.001% were obtained. 8, 9 In another study in which mobilized CD34 + cells were used as targets, the average long-term marking rates with a Moloney leukemia virus vector containing a ribozyme were 0.001-0.01%. 10 Thus, methods for more efficient and potentially safer gene transfer of anti-HIV transgenes to HSCs are needed. Efficient gene delivery to T cells has been achieved using lentiviral vectors that express an antisense transcript to HIV env. 11 However, producing lentiviral vectors with other transgenes that target HIV packaging functions has reduced titers, 12, 13 which affects their utility, although redesign of packing plasmids may overcome this obstacle.
Foamy viruses (FVs) are non-pathogenic, [14] [15] [16] integrating retroviruses with several properties that distinguish them from g-or lentiviruses. FV vectors have improved from early replication competent vectors to thirdgeneration vectors that do not contain detectable replication competent retroviruses. 17, 18 FV vectors can efficiently transduce pluripotent murine 19 and human repopulating cells assayed using a murine xenotransplantation model. 20, 21 Importantly, foamy vectors efficiently transduce repopulating cells in the canine model, 22 which has more closely reflected efficacy in clinical trials. Significant silencing of FV vector transgenes in murine, canine or human repopulating cells was not observed in these studies. FV vectors also have a distinct integration profile from g-and lentiviral vectors, 23 which may reduce their risk for leukemia in a gene therapy setting.
In this study we developed combinatorial anti-HIV FV vectors for AIDS gene therapy that also contain the P140K mutant of the O 6 -methylguanine-DNA methyltransferase (MGMT) gene to allow for in vivo selection after HSC transplantation. MGMT confers resistance to methylating agents, such as temozolomide, as well as to nitrosoureas, such as bis-chloroethyl-nitrosourea (BCNU), and allows for efficient selection at the stem cell level in large animal models (reviewed in Trobridge et al. 24 ). The MGMT protein is expressed in normal human tissues, so in order to enhance selection, O 6 -benzylguanine (O6BG) is used to inactivate endogenous MGMT. The mutant P140K MGMT transgene confers resistance to O6BG 25, 26 so that an alkylating agent, such as BCNU or temozolomide, used in conjunction with O6BG allows for efficient selection of transduced hematopoietic repopulating cells in vivo. [27] [28] [29] We evaluated the ability of combinatorial FV anti-HIV vectors that also contain a MGMT transgene to inhibit HIV-1 and also simian-human immunodeficiency virus (SHIV) replication. SHIV chimeras contain the HIV-1 env, rev, tat, and vpu genes on a background of SIVmac and readily infect macaques. 30 The SHIV-macaque model is an excellent preclinical setting to test AIDS gene therapy strategies, as the transgenes that target the HIV-1 components of SHIV can be assessed in this model. We also evaluated the engraftment of FV-transduced human CD34 + cells and MGMT-mediated in vivo selection of human hematopoietic repopulating cells using an anti-HIV FV vector in a mouse xenotransplantation assay.
Results

Foamy virus (FV) anti-human immunodeficiency virus (HIV) vectors
The foamy vector plasmid, FV-SMPGW, contains the P140K version of MGMT for in vivo selection driven by a spleen focus-forming virus (SFFV) promoter, and also an enhanced green fluorescent protein (EGFP) reporter gene driven from the human phosphoglycerate kinase (PGK) promoter, as a platform to carry anti-HIV transgenes ( Figure 1 ). To enhance MGMT and EGFP expression in vivo, a safety-modified woodchuck post-transcriptional regulatory element that does not express the partial X open reading frame (ORF) 31 Figure 1 The foamy virus (FV) vectors. The FV vector, FV-SMPGW, contains a spleen focus-forming virus (SFFV) promoter (S) driving expression of the P140K mutant of methylguanine methyltransferase (MGMT) (M) and also contains a human phosphoglycerate kinase (PGK) promoter (P) driving expression of enhanced green fluorescent protein (EGFP) (G). This vector also contains a safety-modified woodchuck hepatitis post-transcriptional regulatory element (WPRE) (W). The following anti-human immunodeficiency virus (HIV) transgenes were added to this vector: a human U6 polymerase (Pol) III promoter that expresses a short hairpin RNA (shRNA) targeted to tat/ rev at site I (FV-UsI-SMPGW), a human H1 Pol III promoter-driven shRNA targeted to tat/rev at site I (FV-HsI-SMPGW), a combinatorial cassette with H1 promoter driving short hairpin RNAs (shRNAs) targeted to tat/rev at site I and site II and to human CCR5 at bp 1023 (FVHsIHsIIHR5-SMPGW),a combinatorial cassette with the U6 promoter driving shRNAs targeted to tat/rev at site I and site II and to human CCR5 at bp 741 (FV-UsIUsIIHR5-SMPGW), the transmembrane-localized C46 HIV envelope fusion inhibitor expressed from the SFFV promoter with an internal ribosome entry site (IRES) expressing MGMT (FV-SC46-IMPGW), the U6-driven tat/rev site I shRNA combined with the C46-expressing vector (FV-UsI-SC46-IMPGW) and the combinatorial H1-driven cassette with shRNAs targeted to tat/rev at site I and site II and to human CCR5 at bp 1023 combined with the C46-expressing vector (FV-HsIIHsIHR5-SC46-IMPGW). The control FV vector, FV-PYW, has the human PGK promoter driving enhanced yellow fluorescent protein (EYFP) (Y). The long terminal repeats (LTRs) and foamy cis-acting region (CAR) are also indicated.
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H-P Kiem et al configuration because in previous experiments in the canine and macaque model, we have observed efficient MGMT-based selection at the stem cell level using the SFFV promoter in lentiviral vectors (HP Kiem and GD Trobridge, manuscript under review), and have also observed efficient EGFP expression from the PGK promoter in both myeloid and lymphoid lineages in large animal models. 22, 32 The FV vectors that we developed contain several safety features, including a U3-deleted long terminal repeat (LTR) and two engineered stop codons to eliminate FV gag gene expression from the cis-acting region (CAR) required for efficient gene transfer. The FV vector system does not encode the foamy transcriptional transactivator Tas (earlier called Bel-1), which is required for transcription from the LTR, 33, 34 and hence these FV vectors are self-inactivating. The anti-HIV transgenes we used target HIV-1 genes that are also in the chimeric SHIV. We used this approach so that in future studies these FV vectors could be assessed in a pig-tailed macaque model for AIDS gene therapy. Vectors that are effective in this model could then be tested in clinical studies as the anti-HIV transgenes would not change. Rapid escape of HIV-1 has been shown for single short hairpin RNA (shRNA) therapeutics, 35 and hence combinatorial cassettes were developed in an attempt to reduce the potential for escape from a single anti-HIV shRNA. We evaluated transgenes that target a site I (sI) or a second site II (sII) in HIV-1 tat and rev, 36, 37 which are also in SHIV, inhibit fusion mediated by the HIV-1 env, which is also in SHIV, or target CCR5 (chemokine (CC motif) receptor 5) expression, which affects macrophage-tropic strains of HIV-1 and SHIV. Homozygous CCR5-negative individuals resist HIV-1 infection without apparent immune dysfunction, 38, 39 and hence CCR5 is a clinically relevant target. We first compared CCR5-specific shRNAs using the psiCHECK system (Promega, Madison, WI, USA) and identified two effective shRNA target sites in CCR5 (Supplementary Figure 1) . Two shRNA combinatorial cassettes were synthesized that expressed shRNAs using either human U6 polymerase (Pol) III promoters, or H1 Pol III promoters. A previous study had shown that the U6 promoter, which has a higher expression level than the H1 promoter, may reduce the fitness of transduced primary human T lymphocytes. 40 The two cassettes were introduced into FV-SMPGW to create FV-HsIHsIIHR5-SMPGW, which has two tat/rev shRNAs and a CCR5 shRNA, each driven by a separate H1 promoter; and FV-UsIUsIIUR5-SMPGW, which has two tat/rev shRNAs and a different CCR5 shRNA, each driven by a separate U6 Pol III promoter (Figure 1) . We also evaluated a membrane-anchored C46 peptide that contains a partial ORF from the HIV envelope transmembrane subunit spanning from aa 628 to 673 of gp41. 41 For the C46 transgene, the signal peptide of the low-affinity nerve growth factor receptor directs translocation into the endoplasmic reticulum, and the human immunoglobulin G2 hinge fused to the truncated CD34 membranespanning domain serves as a scaffold to anchor the peptide to the cell surface. High-level expression of the C46 fusion inhibitor is required for a potent antiviral effect, 42 and hence we expressed C46 from the strong SFFV promoter and expressed MGMT from an encephalomyocarditis virus internal ribosome entry site (IRES). We chose this configuration because expression from an IRES leads to lower levels of expression than the transgene expressed from the promoter 5 0 to the IRES. 43 Thus, higher levels of C46 expression should be obtained relative to MGMT. Following selection with BCNU and O6BG, cells expressing lower levels of MGMT would have a selective disadvantage, and cells surviving BCNU selection might have even higher levels of C46 than unselected cells.
Improved foamy virus (FV) helper plasmids
Previously described helper constructs contain significant overlapping regions between the Gag, Pol and Env helper constructs. 18 Ideally, there would be no overlap between helper plasmids so that recombination between helper plasmids, which may potentially lead to a replication competent retrovirus, would be reduced. Toward this goal, we generated foamy Gag, Pol and Env helper constructs (Figure 2 ) that do not overlap (pFMYGagCO and pFMYPol) or that have very limited overlap (31 nt of 100% identity for pFMYPol and pFMYEnv) between adjacent helper genes. The pFMYGagCO helper has the terminal 259 aa codons of the Gag ORF replaced with a codon-optimized gag sequence mutated to eliminate identity to the 5 0 region of the Pol helper plasmid. The identity between the 3 0 region of pol and the 5 0 region of env was reduced by introducing a total of four silent mutations in this overlapping region. We found that these helpers gave similar titers to previously published helper constructs, 18 typically approximately 1 Â 10 6 transducing units (TU) ml À1 unconcentrated and 4 Â 10 7 TU ml À1 after 100-fold concentration for FV-SMPGW and, as expected, do not generate detectable replication-competent retrovirus. Importantly, the addition of the anti-HIV transgene cassettes evaluated here had a negligible impact on titers. For example, we were able to produce the combinatorial vector FV-HsIIHsIHR5-SC46-IMPGW at a concentrated titer of 3.8 Â 10 7 TU ml
À1
. For two combinatorial vectors, FV-HsIIHsIHR5-SMPGW and FV-UsI-SC46-IMPGW, We incorporated the P140K mutant MGMT 25 into our vectors to allow us to increase the percentage of protected cells after transplantation. The MGMT cassette could be used to expand protected gene-modified cells in an AIDS gene therapy. We evaluated the expression of MGMT using immunofluorescence after transduction by the vector FV-SMPGW, which expresses both MGMT and EGFP, and compared expression with the control vector FV-PGW that only expresses EGFP (Figure 3a) . MGMT expression was clearly higher in EGFP-positive transduced cells than in EGFP-negative untransduced cells, and only in the vector that contained MGMT.
To confirm the function of the MGMT cassettes, we transduced CEM.NKR-R5 lymphocytes with FV vectors that contain both MGMT and EGFP at multiplicities of infections (MOIs) that gave between 5 and 50% EGFPexpressing cells, and performed several rounds of selection with O6BG and BCNU ( Figure 3b) . As expected over the course of the O6BG and BCNU treatments, the percentage of EGFP-expressing cells increased, resulting in 480% of the EGFP-expressing cells for all vectors tested after five rounds of selection. Efficient selection occurred regardless of whether MGMT was expressed directly from the SFFV promoter (vectors FV-SMPGW and FV-HsIIHsIHR5-SMPGW) or whether it was expressed from IRES on an mRNA driven by the SFFV promoter (vectors FV-SC46-IMPGW, FV-U6shI-SC46-IMPGW and FV-HsIIHsIHR5-SC46-IMPGW).
Foamy combinatorial anti-human immunodeficiency virus (HIV) vectors potently inhibit simian-human immunodeficiency virus (SHIV) infection
We compared the ability of FV vectors with different anti-HIV transgene cassettes to inhibit SHIV infection in vitro. SHIV chimeras contain the HIV-1 env, rev, tat, and vpu genes on a background of SIVmac and can be used to test AIDS gene therapy strategies in a macaque model. We used a challenge assay in which transduced lymphocytes were exposed to SHIV and the supernatants were tested for virus using an assay that allows quantitation of SHIV infectious units as blue foci on transduced cells (blue cell focus-forming unit (BCFU)). 44, 45 This approach allowed us to compare the ability of each vector to inhibit SHIV replication over a period of 3 weeks using a highly quantitative assay for infectious virions produced from FV-transduced cell populations. CEM.NKR-CCR5 lymphocytes were transduced with the different FV vectors, and then selected with O6BG and MGMT to approximately 80% EGFPexpressing cells. To directly compare the relative ability of each transgene cassette to inhibit replication, these FVtransduced polyclonal populations were then enriched using fluorescence-activated cell sorting to 495% of the EGFP-expressing cells before challenge to minimize the effects from residual unprotected cells. We reasoned that sorting gene-modified cells to a similar and a very high level would minimize the effects of different levels of unprotected cells, and would allow for a better comparison of the relative efficacy of the different vectors.
In the first experiment, vectors that expressed the C46 alone, the U6-driven sI shRNA, the triple H1-driven shRNA cassette, the triple U6-driven cassette or a combination of the U6-driven sI shRNA and the C46 transgene, were compared in an in vitro infection assay in which FV-transduced lymphocytes were challenged in triplicate at a relatively low MOI (0.05) (Figure 4a ). There is an additional difference between the H1-and U6-driven cassettes; the H1-driven sI and sII tat/rev shRNAs are shifted À1 bp, relative to the U6 shRNAs, to provide a canonical adenosine as the first transcribed nucleotide. 46 For this in vitro SHIV challenge the virus is an X4 isolate, and hence R5-specific shRNAs would not have contributed to inhibition in this assay. Both the C46 transgene and the triple H1-driven cassette potently inhibited SHIV replication. Importantly, in these experiments FV-transduced cells were in continuous culture for over 5 weeks after vector exposure, and hence the antiviral efficacy observed was due to stable transgene expression. The combination of the U6-driven sI shRNA and the C46 transgene provided potent inhibition of replication. The FV vector with only the U6-driven sI shRNA also inhibited replication, but by day 21 the viral titers had increased dramatically in comparison with the triple H1-driven cassette or the C46 transgene. Interestingly, the H1-driven combinatorial cassette more potently inhibited SHIV infection than the U6-driven cassette.
On the basis of these results, we combined the C46 transgene with the most potent shRNA cassette, HsIIHsIHR5, to create FV-HsIIHsIHR5-SC46-IMPGW. We also created a vector with a single H1-driven sI shRNA, FV-HsI-SMPGW, to compare its effectiveness to the combinatorial HsIIHsIHR5 cassette. We then repeated the challenge assay using three independently generated FV-transduced populations that were O6BG/BCNUselected, sorted to 495% EGFP-expressing cells and then challenged at a 10-fold higher MOI (0.5) (Figure 4b ). At this higher challenge dose, SHIV replicated to over 7 Â 10 4 blue cell focus-forming unit per ml in cells transduced with the control FV-SMPGW vector by day 21 after challenge. The triple H1-driven cassette still potently inhibited replication over 180-fold by day 21 after challenge, and at this last time point the inhibition of SHIV replication was significantly higher than the vector that expressed only a single sI shRNA driven by an H1 promoter. At the higher challenge dose, the C46 transgene again potently inhibited SHIV replication, with over 960-fold reduction at day 14 and by day 21 over 4 logs (no infectious units were detected). FV vectors that contained the C46 in addition to either the single U6-driven sI shRNA or the triple H1-driven HsIIHsIHR5 cassette also potently inhibited replication over 4 logs by day 21 after challenge. The C46 transgene by itself potently inhibited SHIV replication in this assay, and we could not observe additional effects mediated by either the U6-driven sI shRNA or the triple H1-driven cassette, even at this higher MOI.
Comparison of foamy virus (FV) anti-human immunodeficiency virus (HIV) vectors' ability to inhibit HIV-1 and simian-human immunodeficiency virus (SHIV) using a single-cycle infection assay
We next compared the ability of the three best vectors to inhibit SHIV and HIV-1 using a highly quantitative single-cycle infection assay. In this assay the indicator MAGI-CCR-5 cell line was transduced with FV anti-HIV vectors, and after 14 days the cells were sorted using flow cytometry to 498% EGFP-expressing cells and infected with approximately 1000 transducing units of either HIV-1 or SHIV. The FV-transduced and challenged MAGI-CCR-5 cells were then evaluated for viral replication 48 h after infection. The MAGI-CCR-5 cell line detects both SHIV and HIV-1 infection, so this approach allowed us to directly compare the relative ability of our three best vectors to inhibit SHIV and HIV-1 infection during only one round of infection. For each FV anti-HIV vector, the fold reduction in infected cells is reported, relative to cells transduced with the control vector FV-SMPGW (Figure 4c ). The FV vector expressing C46 provided approximately 15-to 20-fold inhibition of viral replication. In this assay we observed a dramatic reduction of infected cells as determined by activation of the LTR-driven b-galactosidase transgene in the indicator cell line, and thus most C46-expressing cells had no evidence of infection. However, we cannot rule out that some cells, possibly those with lower C46 expression, may have been infected. The FV vector that also contained the U6 driven cassette inhibited infection to a lesser extent, and the FV vector with the triple 
Copy number analysis and analysis of recombination
We determined the average proviral vector copy number in the transduced human lymphocytes used for the above SHIV challenge experiments using real-time PCR. We found that all anti-HIV vectors were similar in copy number, which varied by less than 3.3-fold (Supplementary Figure 3a) . Interestingly, we found that the vectors with U6-driven cassettes had the lowest copy numbers. Recombination events during reverse transcription have previously been described for lentiviral vectors with tandem Pol III promoters. 47 We evaluated potential recombination in our foamy vectors using PCR primers that flanked the shRNA expression cassettes (Supplementary Figures 3b and c) . We found that the tandem triple U6 vector had efficiently recombined, which likely explains the lack of antiviral activity we observed for this vector. For the two FV vectors that contained tandem triple H1-driven cassettes, we observed evidence of partial recombination, with products corresponding to a single R5 shRNA, two shRNAs and the intact triple H1-driven cassette. Despite this partial recombination, the triple H1-driven cassette inhibited replication (Figure 4) , and we could detect expressions of both the sI and sII shRNAs. As expected, there was no evidence of recombination for vectors with single shRNA cassettes.
Evaluation of anti-HIV transgene expression from foamy virus (FV) anti-HIV vectors
We evaluated C46 expression by transducing HT1080 cells with either the control vector, FV-SMPGW, or the anti-HIV vector, FV-SC46-IMPGW, that expresses the C46 fusion inhibitor. After vector exposure, cells were cultured for over 3 weeks and C46 expression was evaluated using immunofluorescence. High-level C46 expression was readily detected in transduced EGFPpositive cells in the FV-SC46-IMPGW vector but not in the untransduced EGFP-negative cells, nor in the FV-SMPGW control vector that does not contain the C46 transgene (Figure 5a) .
We also evaluated the expression of small interfering RNAs (siRNAs) in transduced CEM.NKR-CCR5 lymphocytes using northern blot analysis. We were able to detect siRNA expression for both sI and the sII tat/rev of all FV vectors that contained a corresponding shRNA, whereas siRNA expression was not detected from the vectors FV-SMPGW or FV-SC46-IMPGW that do not contain an shRNA cassette (Figure 5b ). RNA loading was evaluated using a probe to U6 small nuclear RNA. 48 In the vectors that expressed both sI and sII tat/rev shRNAs, both siRNA species could be detected. Expression of the sI tat/rev siRNAs was higher in the U6 Pol III promoter than in the H1 Pol III promoter, as has been observed for lentiviral vectors expressing CCR5 shRNAs. 40 We could detect neither expression of CCR5 siRNAs using northern blot nor a reduction in the level of CCR5 expression using immunostaining (data not shown). It is unclear whether this is due to the relative location of the CCR5 shRNA cassette on the vector (3 0 to the sII and sI cassettes) or whether it is specific to the CCR5 shRNA. However, we had shown that this CCR5 site could be targeted by shRNA, at least when transfected using the psiCHECK system (see Supplementary Figure 1) . Thus, in the two vectors that also contained an H1-driven R5 shRNA cassette, we were unable to detect CCR5-specific siRNA expression or knockdown of CCR5 as determined by antibody staining. This cannot be easily explained by recombination, as the R5 shRNA expression cassette was the 3 0 shRNA and recombination would be expected to leave this cassette intact. However, as expected, based on the SHIV and HIV-1 challenge results, all FV vectors stably expressed the tat/rev siRNAs after MGMT selection.
Engraftment of foamy virus (FV)-transduced human CD34
+ cells in NOD/SCID IL2Rg null mice
To translate an AIDS gene therapy approach to the clinic, it is important to determine whether hematopoietic -benzylguanine (O6BG) and bischloroethyl-nitrosourea (BCNU) and then sorted, total RNA was extracted and analyzed using northern blot. The top-left panel was hybridized to a site I tat/rev probe, and the top right was hybridized to a site II tat/rev probe. In the bottom panels, U6 small nuclear (snRNA) was probed as a control for RNA loading. The detected site I and site II siRNAs are approximately 21 nucleotides.
Foamy Anti-S/HIV vectors H-P Kiem et al
repopulating cells transduced with proposed anti-HIV vectors can efficiently expand and also engraft. We did not observe large differences in the percentage of human CEM.NKR-R5 lymphocytes obtained after transduction with the various anti-HIV cassettes, or in the expansion of these cells during O6BG and BCNU selection (see Figure 3) . However, to address this issue more carefully, we transduced human CD34 + cells and evaluated potential toxicity in progenitors and also engraftment in the NOD/SCID IL2Rg null mouse model that allows for robust engraftment of human severe combined immunodeficiency (SCID)-repopulating cells (SRCs). 49 For these studies we created a control vector, FV-PYW, (Figure 1 
-test).
In these studies the size of control EYFP and anti-HIV EGFP colonies were variable, but there was no obvious difference in overall colony size for the FV-HsIIHsIHR5-SC46-IMPGW progenitors and the control FV-PYW progenitors. Thus, there was no evidence that expression of the anti-HIV transgene cassette altered the growth of human CD34-derived progenitors.
To assess the effects of the MGMT and anti-HIV cassettes on engraftment, we performed a competitive repopulation experiment in NOD/SCID IL2Rg null mice. The EYFP protein differs by only 5 aa with EGFP and can be easily discriminated using flow cytometry and, thus, is an excellent marker for this purpose. We performed this competitive repopulation transplant in a cohort of five mice using human CD34 + cells transduced with our combinatorial vector FV-HsIIHsIHR5-SC46-IMPGW (arm 1) or the control vector FV-PYW (arm 2). In this experiment, two different vector stock preparations were used for each vector, and the order of injection of each arm was alternated to control for the potential effect of these variables on engraftment. One animal died before the first analysis at 5 weeks, and engraftment and marking were analyzed in the bone marrow of the remaining four mice at 5 weeks after transplantation. Engraftment was high, and the marking levels in vivo closely matched what we observed in the human CD34 + cultures before transplant ( Figure 6 ). An MOI of 2, based on transduction of human HT1080 cells, was used for both the experimental arm FV-HsIIHsIHR5-SC46-IMPGW and the control arm FV-PYW. Marking was significantly higher for the FV-PYW control arm in pretransplantation liquid cultures and in the bone marrow at 5 weeks after transplantation. However, there was no significant difference in the marking levels in liquid cultures pre-transplantation and the marking in the bone marrow BM at 5 weeks for either the control vector, FV-PYW, (P ¼ 0.35) or for the combinatorial anti-HIV vector, FV-HsIIHsIHR5-SC46-IMPGW, (P ¼ 0.15). These data show that the anti-HIV and MGMT cassettes in the combinatorial FV vector, FV-HsIIHsIHR5-SC46-IMPGW, do not interfere with the engraftment capacity of human CD34 + SRCs.
Expansion of foamy virus (FV)-transduced human SCID-repopulating cells (SRCs)
At 7 and 10 weeks after infusion of FV-transduced cells, we treated the NOD/SCID IL2Rg null mice with O6BG and BCNU to determine if we could increase the percentage of gene-modified cells in vivo. Following these two treatments, the percentage of EGFP-expressing cells increased significantly (Po0.05) for the anti-HIV MGMT vector, FV-HsIIHsIHR5-SC46-IMPGW (Figure 6 ), and marking with the control vector, FV-PYW, decreased as expected. The final marking level was 8.2% for the FV-HsIIHsIHR5-SC46-IMPGW experimental arm. It should be noted that if this vector was used without a control arm, the marking would be expected to be twice as high, approximately 16%. In summary, human SRCs 
Discussion
In this study we developed FV vectors with combinatorial anti-HIV cassettes that confer potent protection from both HIV-1 and SHIV infection and show their efficacy for HSC gene transfer. These vectors also express an EGFP reporter gene for facile detection of transduced cells in vivo, and an MGMT cassette to allow for selection of protected cells after transplantation.
FV vectors have been developed for gene therapy approaches and have several advantages, including their large packaging capacity 18 and their ability to efficiently transduce hematopoietic repopulating cells. 19, 20, 22 FV vectors are particularly advantageous for AIDS gene therapy because foamy retrovirus has low nucleotide sequence homology with HIV, 50 and hence mobilization of foamy vector proviruses in transduced cells by wildtype HIV infection will not be a consideration. 51 In addition, expression of anti-HIV transgenes that target HIV packaging functions and greatly reduce HIV-1-based lentiviral titers 8, 13 do not adversely affect foamy vectors (Taylor et al. 52 and our data). The ability to efficiently deliver anti-HIV transgenes that cannot be delivered by HIV-1-based lentiviral vectors is a key advantage of FV vectors for AIDS gene therapy. We observed that FV vector titers were not adversely affected by transgene cassettes that greatly reduced lentiviral titers.
Previous studies have shown that a U6-driven shRNA that targets tat and rev can protect from SIV or HIV-1 infection when introduced using foamy vectors. 52, 53 However, protection from single shRNAs can be rapidly overcome by single-base-pair mutations. 35 We observed an increase in viral replication at later time points when an FV vector with a single tat/rev shRNA was used to inhibit SHIV replication, but observed potent inhibition in vitro when this shRNA was combined with an additional tat/rev shRNA. When we combined our combinatorial H1-driven shRNA cassette with the C46 fusion inhibitor, we observed a 420-fold reduction in a single-cycle infection assay, and a 410 000-fold reduction in a challenge assay that evaluates multiple cycles of virion production and infection. In both assays, cells were transduced at relatively low MOIs and maintained stable resistance to viral infection. Even after MGMTmediated selection and extensive culture, transduced lymphocytes remained highly protected from SHIV infection. We did observe efficient recombination between tandem shRNA cassettes using three U6 Pol III promoters, and partial recombination when using three H1 promoters. We combined a total of six transgenes, four anti-HIV transgenes, MGMT, and EGFP into the vector, FV-HsIIHshIHR5-SC46-IMPGW, and were able to show stable expression and function in five out of six of these transgenes. However, we could not detect expression or function for the H1-driven CCR5 shRNA in this vector, or in the FV-HsIIHsIHR5-SMPGW vector. Despite the absence of detectable R5-specific siRNA expression, this combinatorial vector that expressed three anti-HIV transgenes potently inhibited both SHIV and HIV-1 infection. Future combinatorial shRNA FV vector designs should take these findings into consideration, and it may be that expression of multiple shRNAs from a microRNA 48 may overcome the above limitations. A previous study showed that a high-level expression of shRNAs from the U6 Pol III promoter impaired the ability of transduced lymphocytes to expand, and that expression of a CCR5 shRNA from a H1 Pol III promoter was well tolerated in macaque HSCs. 54 We thus developed an anti-HIV cassette in which three shRNAs were each driven by three H1 promoters and found that this cassette potently inhibited SHIV and HIV-1 replication and did not impair engraftment of human SRCs. Ectopic expression of the C46 fusion inhibitor had previously been shown not to induce major toxic effects in transplanted murine hematopoietic cells. 55 Interestingly, we found that FV vectors with H1-driven cassettes were effective, showing that higher-level expression was not necessary for a potent antiviral effect. Human SRCs transduced with FV vectors that express the P140K mutant form of MGMT and a combinatorial anti-HIV cassette were able to efficiently engraft NOD/SCID IL2Rg null mice. The competitive repopulation assay showed that this FV vector engrafted as efficiently as the control FV vector, when compared with the relative pre-transplant marking in CD34 + cells. Thus, expression of FV vector-delivered H1-driven tat/rev shRNAs does not seem to compromise SRC engraftment. The mouse xenotransplantation model may overestimate transduction of primate HSCs, 56 and hence future studies to evaluate transduction of nonhuman primate long-term repopulating cells with FV vectors will be of great value in moving this approach to the clinic. However, the NOD/SCID IL2Rg null competitive repopulation model we have described here should be an excellent way to compare potential off-target effects of anti-HIV cassettes, including cassettes that mediate RNA interference.
The FV vectors that we describe in this study target steps of the HIV-1 replication cycle that are also used by SHIV, and hence they can be evaluated in the highly relevant macaque SHIV model, which has played a crucial role in the development of anti-HIV treatment strategies. [57] [58] [59] In this model, MGMT-mediated selection could be used to increase the percentage of FV-transduced cells before challenge to determine if macaques are protected from simian AIDS, toward establishing a proof of concept for AIDS gene therapy. These FV vectors should also be effective in clinical studies, given the potent inhibition of HIV-1 that we have showed. The improved FV helper plasmids that we describe in this study are well suited for future clinical applications. After removing the PGK-EGFP cassette from our FV vectors, they may be particularly effective in a clinical setting of AIDS lymphoma. After autologous transplant with FV-transduced cells, treatment of patients with O6BG and BCNU would not only have an anti-leukemic effect, but should also increase the number of cells protected from HIV-1.
Materials and methods
Foamy virus (FV) methylguanine methyltransferase (MGMT) vectors and helper plasmids
The FV vector plasmid, pFV-SMPGW, was constructed by synthesizing an LTR-fusion promoter with the human Foamy Anti-S/HIV vectors H-P Kiem et al cytomegalovirus immediate-early promoter (CMV) and the FV LTR R and U5 region, in addition to the cis-acting gag region required for efficient foamy replication, followed by a multiple cloning site, and a 3 0 LTR with a deleted FV U3 region and the R and U5 region. This double-stranded DNA fragment was synthesized by Blue Heron Biotechnology (Bothell, WA, USA) using GeneMaker technology according to the sequence specified and inserted into a 2-kb plasmid backbone derived from pUC19 from the SapI to BsmBI site. A 2.3-kb FV cisacting region with the 3 0 region of pol and the 5 0 region of env required for efficient gene transfer 18, 60 was PCRamplified from the FV infectious plasmid pHSRV13 (kind gift from A Dusty Miller, Fred Hutchinson Cancer Research Center) using the primers 5 0 -TTCGAAT TAAGGCTATGGATTTGGCCATGGGAC-3 0 and 5 0 -CAA GGTGTATACTATGAACCCCATCCGGCGCGCC-3 0 . The PCR amplification was performed with Phusion highfidelity DNA polymerase from New England Biolabs (Ipswich, MA, USA) using 5 cycles at 50 1C annealing temperature and 25 cycles at 60 1C annealing temperature following the manufacturer's protocol. This FV cis-acting region was inserted into the synthesized vector at an engineered multiple cloning site. A transgene cassette including the SFFV promoter, P140K MGMT mutant and a PGK promoter driving EGFP and a modified woodchuck post-transcriptional regulatory element was transferred from the previously described lentiviral vector, RSC-SMPGW, 32 to create the FV vector plasmid pFV-SMPGW. To create pFV-PYW, the SFFV-MGMT cassette was removed and the EGFP was replaced with EYFP from the lentiviral vector plasmid, pRRL.sin.cPPT.Pgk.EYFP.pre (a kind gift from Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy).
The foamy helper plasmids were generated by PCR amplification of the foamy structural genes gag, pol and env from pHSRV13 using Phusion enzyme with the following primers: pFMYGag, 5 0 -CGGCCGGCCACCATGGCTTCA GGAAGTAATGTTGAAGAATATG-3 0 and 5 0 -TTTAGTCT CTTTGGTCTCCGCCGGAAGCGGC-3 0 ; pFMYPol, 5 0 -CG GCCGGCCACCATGAACCCTCTGCAGCTGTTACAGC CGCT-3 0 and 5 0 -TTTACTCATTCTTTTCCAAATGATC CATTGTTGCAGTGTC-3 0 ; and pFMYEnv, 5 0 -CGGCCGG CCACCATGGCCCCACCCATGACACTGCAACAATGG ATCAT-3 0 and 5 0 -AGGCTACTGATTCTTCTTTTTCGTA GGAATC-3 0 . After PCR amplification the genes were subcloned into the NotI sites of pCMVb replacing the b-galactosidase gene. pFMYGagCO was constructed by replacing a 795-bp fragment from the NsiI site in Gag to the 3 0 NotI site after the Gag ORF, with a synthesized fragment with an identical Gag ORF, but with the carboxyl terminus 259 Gag codons optimized for expression in human cells.
Construction of foamy anti-human immunodeficiency virus (HIV) vectors
The anti-HIV shRNA transgenes were inserted into the FV vector plasmids at a SacII site in the vector multiple cloning site 3 0 to the foamy cis-acting region and 5 0 to the MGMT-EGFP transgene cassette. pFV-UsI-SMPGW contains a human U6 Pol III promoter driving expression of a previously described sI shRNA targeted to tat/rev. 36, 37 Plasmids that contain U6 promoters driving expression of shRNAs targeting two sites in human CCR5 were constructed and tested using the psiCHECK (Promega) shRNA system following the manufacturer's protocols. A three-shRNA cassette with three H1 Pol III promoters each driving expression of a shRNA that targets sI, sII HIV-1 tat/rev, 36, 37 or a 21-bp CCR5 shRNAs targeting bp 1023-1043 of human CCR5 was synthesized and subcloned into the pFV-SMPGW plasmid, creating pFV-HsIIHsIHR5-SMPGW. For the H1-driven cassette HsIIHsIHR5, we modified the previously described sI and sII tat/rev shRNAs and the CCR5 1024 shRNA by shifting the shRNAs À1 bp, so that the start site would be an adenosine, the canonical first nucleotide used by the H1 promoter. 46 pFV-UsIIUsIUR5-SMPGW was made by inserting a synthesized cassette with three U6 promoters, driving expression of a sI tat/rev shRNA, a sII tat/rev shRNA and a CCR5 shRNAs designed to bp 741-761 of human CCR5 into the pFV-SMPGW plasmid. The single H1-driven shRNA foamy vector plasmid, pFV-HsI-SMPGW, was constructed by deleting the other two H1-driven shRNA cassettes out of pFV-HsIIHsIHR5-SMPGW using unique restriction sites engineered between the H1 promoter-shRNA cassettes. The C46 anti-HIV peptide contains a partial ORF from the HIV envelope protein transmembrane subunit spanning from aa 628 to 673 of gp41. 41 To create pFV-SC46-IMPGW, the C46 transgene was amplified by PCR using primers 5 0 -CC AGGTACCGCTCTAGCGCTACCGGTC-3 0 and 5 0 -CCAG GTACCGCTGGAGCTCTCCGGATCAG-3 0 , and the PCR product was introduced into the Acc65 I sites of pFV-SMPGW to create pFV-SC46-PGW. The IRES-MGMT was then introduced by ligating a FseI to BsiWI fragment of MP71.C46.IRES2.MGMT.Pre (a kind gift of Chris Baum, Hannover Medical School, Hannover, Germany) to create pFV-SC46-IMPGW. pFV-UsI-SC46-IMPGW and pFVHsIIHshIHR5-SC46-IMPGW were constructed by combining pFV-SC46-IMPGW with either pFV-UsI-SMPGW or pFV-HsIIHshIHR5-SMPGW using standard cloning techniques. The sequences of foamy vector, helper plasmids and transgene cassettes are provided in Supplementary Table 1 .
Cell culture
Human 174 Â CEM cells (Cat#272), 61 CEM.NKR-CCR5 (Cat#4376) 62 and MAGI-CCR-5 cells 45 (Cat#3522) were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, from Drs Peter Cresswell, Alexandra Trkola and Julie Overbaugh, respectively. Iscove's modified Dulbecco's medium was used to culture 174 Â CEM cells and CEM.NKR-CCR5 cells. MAGI-CCR-5 cells and human embryonic kidney 293 cells were cultured in Dulbecco's modified Eagle's medium. All cultures were supplemented with 10% heat-inactivated (56 1C for 30 min) fetal bovine serum (HyClone, Logan, UT, USA), unless otherwise stated, with 100 U ml À1 of penicillin and 100 mg ml À1 of streptomycin, and were incubated at 37 1C in a 5% CO 2 atmosphere. Human CD34 + cells were collected from volunteers as part of an institutional review board-approved protocol, isolated using magnetic beads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions, and were stored in liquid nitrogen until use.
Preparation of foamy virus (FV) vector stocks
Foamy vector stocks were produced using either calcium phosphate transfection or polyethylenimine transfection.
Foamy Anti-S/HIV vectors H-P Kiem et al
Calcium phosphate transfection was performed essentially as previously described, 18 except that 15 mg of the vector plasmid was used with 15 mg of the foamy Gag helper pFMYGagCO plasmid, 6 mg of the Pol helper plasmid pFMYPol and 1.5 mg of the Envelope helper plasmid pFMYEnv. For polyethylenimine transfection, 63 14 mg of the vector, 14 mg of the foamy Gag helper pFMYGagCO, 5.6 mg of the Pol helper pFMYPol and 1.4 mg of the Env helper pFMYEnv were mixed in 2 ml of serum-free medium. Then 105 ml of 1 mg ml À1 polyethylenimine, was added to the diluted DNA dropwise and the solution was immediately vortexed for 10 s and incubated at room temperature for 15 min. The DNA/ polyethylenimine mix was then added evenly over a 10-cm tissue culture dish. The next day, at approximately 16 h after transfection, the medium was replaced with medium supplemented with 2 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. The vector was harvested at 72 h after transfection and concentrated 100-fold, as previously described. 18 For the NOD/SCID IL2Rg null mouse studies, 5% dimethyl sulfoxide was added to the vector stocks and frozen at À80 1C. These frozen vector preparations were thawed, and the dimethyl sulfoxide was removed by dialysis with Iscove's modified Dulbecco's medium using a Microcon Ultracel YM-50 centrifugal filter (Millipore, Billerica, MA, USA) just before use.
Preparation of human immunodeficiency virus (HIV) and simian-human immunodeficiency virus (SHIV) challenge virus
The following viruses and infectious virus plasmids were obtained through the AIDS Research and Reference Reagent Program from the following investigators: SHIV KU-1 was obtained (Cat#3441) from Dr Opendra Narayan and Dr Sanjay Joag, and HIV-1 89.6 64 (Cat#1966) was obtained from Dr Ronald Collman. Both SHIV KU-1 and HIV 89.6 were amplified by passage on 174 Â CEM cells, 0.22-mm filtered and stored frozen at À80 1C before use. Virus preparations were titered using MAGI-CCR-5 cells as previously described, 44 and the number of bgalactosidase-positive foci was enumerated using microscopy.
Anti-S/HIV assays and methylguanine methyltransferase (MGMT)-mediated selection in vitro
For in vitro challenge assays, CEM.NKR-CCR5 cells were transduced with FV vectors at an MOI between two and five and selected using O6BG and BCNU to 480% EGFP-positive cells, and were then sorted to 495% EGFP-positive cells before challenge. O6BG and BCNU (Sigma, St. Louis, MO, USA) were made up at stock concentrations of 50 mM in 100% dimethyl sulfoxide and 10 mM in 10% ethanol, respectively, and stored frozen at À80 1C until use. O6BG and BCNU were used at final concentrations of 50 mM and 10 mM, respectively, for the selection of FV-transduced CEM.NKR-CCR5 cells. The cells were exposed to O6BG for 1 h before BCNU was added. For challenge, the cells were first plated overnight at a density of 2 Â 10 6 cells ml À1 , and then the next day plated for challenge at 2 Â 10 4 cells in 100 ml in a 48-well plate in triplicate. Challenge virus was added at an MOI of 0.05 or 0.5. During the 3-week challenge, cells were passaged at a ratio of 1:3 into fresh medium every 2-3 days. Medium containing infectious SHIV was removed from the infected cultures at the indicated times and centrifuged at 2000 g for 5 min to pellet cells. Supernatant containing virus was then added to MAGI-CCR-5 cells to determine the titer as described above.
For the single-cycle HIV-1 and SHIV assays, the HIV-1 and SHIV indicator, MAGI-CCR-5 cell line, was transduced in triplicate with FV anti-HIV vectors at an MOI of three. The cells were sorted using flow cytometry for EGFP expression to 498% EGFP-expressing cells. For each vector, these polyclonal cell lines were plated and infected with approximately 1000 transducing units of either the HIV-1 isolate HIV89.6 or the SHIV isolate KU-1. The MAGI-CCR-5 cells were then evaluated for SHIV and HIV-1 replication 48 h after infection as described above. For each anti-HIV vector, the fold reduction in infected cells was calculated as the number of infected b-galactosidase-expressing foci relative to the number of infected b-galactosidase-expressing foci for the control vector FV-SMPGW. 
Methylguanine methyltransferase (MGMT) and C46 immunostaining
Analysis of copy number and recombination
The relative marking levels in foamy transduced CEM.NKR-CCR5 lymphocytes was analyzed using quantitative real-time PCR assay. We amplified 300 ng DNA in duplicate with a woodchuck post-transcriptional regulatory element-specific primer/probe combination ( Detection of small interfering RNA (siRNA) expression by northern blot FV vector-transduced CEM.NKR-CCR5 lymphocytes were selected using O6BG and BCNU to 480% EGFPpositive cells, then sorted to 495% EGFP-positive cells, and total RNA was isolated using STAT-60 (Tel-Test, Friendswood, TX, USA) reagent according to the manufacturer's recommendations. Ten micrograms of total RNA was run on a 10% TBE-Urea Ready Gel (BioRad Laboratories, Hercules, CA, USA), together with a size marker, and then electrotransferred to a Hybond N + membrane (GE Healthcare, Piscataway, NJ, USA). The membrane was baked at 80 1C for 2 h and then prehybridized for 3 h at 37 1C in QuikHyb hybridization buffer (Stratagene, La Jolla, CA, USA) with 100 mg ml À1 final concentration of salmon sperm DNA. The membrane was then hybridized overnight in QuikHyb hybridization buffer at 37 1C with 5 pmol of oligonucleotide DNA, probe-end labeled with g-[
32 P]-ATP using 10 units of polynucleotide kinase (Invitrogen). The shRNA probes used were: tat/rev sI 5 0 -GCGGAGACAGCGACGA AGAG-3 0 and tat/rev sII 5 0 -GCCTGTGCCTCTTCAGC TAC-3 0 . After hybridization the membrane was then briefly washed in a 6 Â SSPE buffer (20 Â SSPE is 3 M NaCl, 0.2 M NaH2PO4 and 0.02 M ethylenediaminetetraacetic acid, pH 7.4), then exposed using a Molecular Dynamics storage phosphor screen (GE Healthcare) for 1 week and analyzed using a Typhoon Trio variable mode imager (GE Healthcare) and ImageQuant TL (GE Healthcare) software. To evaluate RNA loading, the blots were stripped with 1% sodium dodecyl sulfate at 85 1C for 30 min and washed, then hybridized as described above using a U6 small nuclear RNA probe 5 0 -TATGGA ACGCTTCTCGAATT-3 0 .
Xenotransplantation studies in the NOD/SCID IL2Rg null mouse model using a competitive repopulation approach
The mice were housed at the Fred Hutchinson Cancer Research Center under conditions approved by the American Association for Accreditation of Laboratory Animal Care. The study protocols were approved by the institutional animal care and use committee. Human CD34 + cells were thawed and cultured in transduction medium (Iscove's modified Dulbecco's medium with 10% heat-inactivated fetal bovine serum, 100 ng ml À1 each of Flt-3 ligand, stem cell factor, thrombopoietin, interleukin-3, interleukin-6 and granulocyte colony-stimulating factor) overnight before vector addition. For each experimental arm of the competitive repopulation assay, 7.5 Â 10 5 human CD34 + cells were added to one well of a 12-well plate pretreated with CH-296 fibronectin fragment (Takara, New York, NY, USA) at 2 mg cm À2 and exposed overnight to vector at an MOI of two in transduction medium. In the following morning, cells were washed with D-PBS, and cells from each well were resuspended in 200 ml of D-PBS and injected by tail vein into previously irradiated NOD/SCID IL2Rg null mice (no. 005557, The Jackson laboratory, Bar Harbor, ME, USA). The mice were irradiated with 250 cGy from a 137 Cs source at 89.5 cGy min À1 using a Mark I series 30 irradiator (JL Shepherd and Associates, San Fernando, CA, USA) the day before infusion. To determine the transduction efficiency, CD34 + cells were cultured in transduction medium, and the percentage of EGFPpositive cells was determined using flow cytometry on day 3 and on day 10 after vector exposure. Bone marrow aspirates were obtained from the femur using a 28-gauge needle. The bone marrow cells were incubated in hemolytic buffer, then washed with D-PBS with 2% fetal bovine serum and incubated at 4 1C for 30 min with phycoerythrin-labeled mouse anti-human CD45-specific antibody (BD Pharmingen, Franklin Lakes, NJ, USA, Cat. no. 555483) or isotype control (BD Pharmingen Cat. no. 555749), and then washed twice in D-PBS with 2% fetal bovine serum and analyzed using flow cytometry. For in vivo selection, mice were treated with 5 mg per kg O6BG and 7.5 mg per kg BCNU at 7 weeks and 10 weeks post-transplant by intraperitoneal injection. O6BG was prepared at a stock concentration of 1 mg ml À1 in 40% PEG-400 and 60% D-PBS. BCNU was prepared in 10% ethanol at a stock concentration of 10 mM. O6BG was diluted to 0.2 mg ml À1 in 0.9% saline and administered using intraperitoneal injection in split doses at 1 h and at 45 min before BCNU administration.
